Pommeraie collaborative COPD strategy
La Pommeraie's Collaborative COPD Strategy, with Boehringer Ingelheim Canada's Patient Access division, focuses on enhancing COPD patients' health and reducing hospitalizations.
Search
Ontario
Boehringer Ingelheim Canada collaborates with premier institutions in Ontario to drive innovative solutions for high-quality healthcare. Click to read more.
Alberta
Learn about Boehringer Ingelheim Canada's strategic partnerships with leading institutions in Alberta to advance quality healthcare.
Quebec
Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.
Western Canada
Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.
Anna Dieckmann
Anna Dieckmann talks about professional fulfilment and possibilities for the future in her role in Information Technology.
The Research Process
Science and Innovation - Animal Health Innovation - Parasiticides
Mental Health
Mental Health
Retinal Diseases
Retinal Diseases
Home Health Monitoring
Read more about the HHM Project that provides a community-based home health monitoring digital solution for people living with chronic conditions.
Innovative health projects impact thousands of Indigenous Peoples in Canada
Innovative health projects impact thousands of Indigenous Peoples in Canada
Ensho Health
Boehringer Ingelheim Canada, community cardiologists, and Ensho Health collaborated to create a tool optimizing care for chronic conditions in Alberta. More info.
Spark Innovation Challenge
The Type 2 Spark Innovation Challenge encourages innovation, collaboration and change in approaches to addressing T2D in British Columbia. Continue reading.
ABIC-COPD
Discover the ABIC Fund, developed to advance health innovation projects in the area of respiratory diseases, like COPD, for Alberta-based investigators.
Virtual care pharmacy services offered in Alberta long-term care facilities
Virtual care pharmacy services offered in Alberta long-term care facilities
Accessible Customer Service Policy
Accessible Customer Service Policy
Business Ethics
The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.
Effective management practices for parasite control in cattle
Effective management practices for parasite control in cattle
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas